Companion Cancer Diagnostics Market The rising incidence of cancer worldwide is a primary driver of the Global Companion Cancer Diagnostics ...

The integration will enable Leica’s BOND staining systems to simultaneously detect RNA and protein targets on the same tissue ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

This blog explores the benefits of applying Large Language Models to extract information from pathology reports, allowing us to curate bespoke ...

Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. Target-MRD is a blood test based on ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Jan. 16, 2025 — Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials ... Jan. 16, 2025 — The ...

A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to ...

Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") , a leading provider-centric, technology-powered healthcare company enabling providers to ...

The targeting of telomeres offers promise for new cancer therapies, which can be aimed at disrupting the mechanisms that ...

Cervical cancer symptoms are often absent in the early stages and may only become apparent when the disease is more advanced. Abnormal vaginal bleeding is the most common symptom overall, often ...